Ga-PSMA PET/CT is the upcoming imaging modality for staging, restaging and response assessment of prostate cancer. However, due to neuroendocrine differentiation in some of patients with prostate cancer, they express somatostatin receptors instead of prostate specific membrane antigen. This can be exploited and other modalities like Ga-DOTANOC PET/CT and F-FDG PET/CT should be used in such cases for guiding management. We hereby discuss a similar case of 67-year-old man of adenocarcinoma prostate with neuroendocrine differentiation, which shows the potential pitfall of Ga-PSMA PET/CT imaging and benefit of Ga-DOTANOC PET/CT and F-FDG PET/CT in such cases.
Clinical nuclear medicine. 2018 Feb 23 [Epub ahead of print]
Girish Kumar Parida, Sarthak Tripathy, Shreya Datta Gupta, Abhinav Singhal, Rakesh Kumar, Chandrasekhar Bal, Shamim Ahmed Shamim
From the Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.